However, in a recent meta-analysis of relevant randomized controlled trials, it was shown that SGLT-2 inhibitors do not affect arterial stiffness among subjects with established cardiovascular disease or at high cardiovascular risk, while they confer only a modest but significant reduction in pulse wave velocity, the “gold-standard” of arterial stiffness, among patients with co-existing T2DM [40]. Here, SLC5A2 is linked to type 2 diabetes mellitus.